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Background: Heat shock protein 90 (Hsp90), a chaperone that regulates activity of many client proteins responsible
for cellular growth, differentiation, and apoptosis, has been proposed as an important clinical and preclinical
therapeutic target in a number of malignancies and autoimmune diseases, respectively. In this study, we evaluated
the effects of pharmacological Hsp90 inhibition on human proinflammatory T cell responses.
Findings: Using anti-CD3 antibody-stimulated human peripheral blood mononuclear cell cultures, we observed that
Hsp90 inhibition by non-toxic concentrations of the geldanamycin derivative 17-DMAG significantly blocked T cell
proliferation, reduced IFN-γ and IL-17 expression on CD4+ T lymphocytes, and arrested secretion of proinflammatory
IFN-γ, TNF-α, and IL-17, cytokines characteristic of Th1 and Th17 cells, respectively. These effects were associated
with inhibition of NF-kB activity, upregulation of Hsp70 protein expression, and disruption of T cell-specific
nonreceptor tyrosine kinase Lck activation.
Conclusions: Our results further support the potential use of Hsp90 inhibitors in patients with autoimmune
diseases where uncontrolled Th1 or Th17 activation frequently occurs.
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Heat shock protein 90 (Hsp90) is an ATP-dependent
molecular chaperone that is exploited by malignant cells
to support activated oncoproteins, including many
cancer-associated kinases and transcription factors, but
has been also shown to exert potent immunomodulatory
actions [1,2].
Several pieces of evidence show that Th1 and Th17
cells are pathophysiologically associated with several
autoimmune diseases and that Hsp90 activity is required
for IFN-γ and IL-17 signaling in these cell types, respect-
ively [3-5]. Based on these findings and the observations
that Hsp90 plays important roles in antigen presenta-
tion, activation of lymphocytes, macrophages, and den-
dritic cells [2], we and others claim that pharmacological
inhibition of Hsp90 is a promising therapy to ameliorate
inflammatory cascades in autoimmune diseases [6-11].* Correspondence: Michael.Kasperkiewicz@uk-sh.de
Department of Dermatology, University of Lübeck, Ratzeburger Allee 160,
23538 Lübeck, Germany
© 2014 Tukaj et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.In the present study, we show that blockade of Hsp90
by the geldanamycin derivative 17-DMAG leads to inhib-
ition of T cell proliferation, suppression of IFN-γ and
IL-17 expression on CD4+ T cells, and attenuation of se-
cretion of proinflammatory IFN-γ, TNF-α, and IL-17, cy-
tokines characteristic of Th1 and Th17 cells, respectively.
Methods
Cell culture
Peripheral blood mononuclear cells (PBMCs) were iso-
lated from venous blood of 11 healthy volunteers (age
25-35 years, mean 29.72 ± 3.47, 6 females and 5 males)
by Ficoll-Paque (GE Healthcare Bio-Sciences) gradient
centrifugation and cultured as described previously with
minor modification [12]. Briefly, PBMCs were washed
twice in PBS and resuspended at 0.5 × 105 or 1 × 106
cells per ml of medium (RPMI 1640 supplemented with
10% fetal calf serum, 2 mM L-glutamine, and penicillin/
streptomycin). Cells were cultured in the presence of
1 μg/ml immobilized anti-CD3 mAb (BD Bioscience) intd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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without or with different concentration of 17-DMAG
(InVitrogen) for 24 hours, 72 hours, or 7 days.
The collection of blood samples was approved by the
Ethics Committee of the University of Lübeck, and in-
formed consent was obtained according to the Declar-
ation of Helsinki.LDH cytotoxicity assay
Cytotoxicity of 17-DMAG was measured by a lactate de-
hydrogenase (LDH)-releasing assay using a Cytotoxicity
Detection Kit (Roche) according to the manufacturer’s
protocol and quantified using an ELISA plate reader.
Briefly, PBMCs (1 × 106 per ml) were incubated with 17-
DMAG at different concentrations (0.1, 1, and 2.5 μM)
for 24 hours. Cell lysis was determined by measuring the
amount of LDH released into the culture medium.Proliferation assay
A total of 0.5 × 105 PBMCs were cultured in the pres-
ence of plate-bound anti-CD3 mAb in 96-well plates.
Stimulated cells were cultured alone or with different
concentrations of 17-DMAG (0.1, 1, or 2.5 μM). After
6 days, cells were pulsed with BrdU for further 24 hours.
T cell proliferation was measured using a colorimetric
cell proliferation BrdU ELISA (Roche).Flow cytometric immunophenotyping
For analysis of intracellular cytokines, PBMCs were
stimulated with anti-CD3 mAb without or with 17-
DMAG (0.1 μM) for 72 h hours. A GolgiStop™ Protein
Transport Inhibitor (BD Pharmingen™) was added to-
gether with phorbol-12-myristate-13-acetate (PMA)
(50 ng/ml) and ionomycin (1 μg/ml) (Sigma) for the last
5 hours. Cells were washed, fixed, permeabilized, and
stained for detection of intracellular cytokines using the
following anti-human mAbs: anti-IFN-γ-FITC, anti-IL-
17-PE, and anti-CD4-PERCP-CY5.5 (BD Pharmingen).
Samples were analyzed using FACSCalibur flow cyt-
ometer (BD).Cytokine measurement
Supernatants of PBMC cultures were collected after a
72-hour treatment period with anti-CD3 mAb in ab-
sence or presence of 17-DMAG (0.1 μM). Supernatants
were taken from cultures non-treated by GolgiStop,
PMA, or ionomycin. Twelve cytokines (IL-2, IL-4, IL-5,
IL-6, IL-10, IL-12, IL-13, IL-17A, IFN-γ, TNF-α, G-CSF,
and TGF-β1) were measured by a Human Th1/Th2/
Th17 Cytokines Multi-Analyte ELISArray Kit (Qiagen
Biosciences).Determination of NFκB p65 activity
For analysis of NFκB p65 activity, PBMCs were stimu-
lated with anti-CD3 mAb without or with different con-
centrations of 17-DMAG (0.1, 1, and 2.5 μM) for
24 hours. NFκB p65 activity was measured in cell lysates
by a NFκB p65 ELISA kit following the manufacturer’s
instruction (Enzo).Immunoblotting
Equal amounts of PBMC lysates were separated by 10%
SDS-PAGE gel and transferred onto nitrocellulose mem-
brane. The membrane was blocked with 3% milk in PBS
for 2 hours, followed by incubation with rabbit poly-
clonal antibodies against NFκB p65 (1:1000; Santa Cruz
Biotechnology, Inc.), Hsp70 (1:100; Stressgen), p-Lck
(Tyr394) (1:1000; Sigma), and β-actin (1:1000; Cell Sig-
naling Technology) at room temperature for 2 hours.
Horseradish peroxidase-conjugated gout anti-rabbit anti-
bodies (1:1000; Dako) were used as secondary anti-
bodies. The bands were visualized using Amersham ECL
Plus Western Blotting Detection Reagents (GE Health-
care). Relative NFκB p65, Hsp70, and p-Lck (Tyr394)
protein concentrations were measured by densitometry.Statistical analysis
Data was analyzed by Student’s t-test or one-way analysis
of variance (ANOVA) using Graphpad prism 5 (San
Diego, California). A P-value <0.05 was considered to in-
dicate a statistically significant difference.Results
17-DMAG arrests proliferation of T cells
To determine whether 17-DMAG affects T cell prolifera-
tion, we isolated human PBMCs from healthy volunteers
and stimulated them with anti-CD3 antibody in the ab-
sence or presence of different amounts of 17-DMAG.
Cell proliferation was assayed by BrdU ELISA. T cell
proliferation was inhibited by 17-DMAG in a dose-
dependent manner (Figure 1A) and this inhibitory effect
was observed upon non-toxic concentrations of the in-
hibitor (Figure 1B).17-DMAG inhibits proinflammatory Th1 and Th17 cell
subpopulations
Next, we investigated the effects of 17-DMAG on proin-
flammatory T cell subpopulations [CD4+IFN-γ+ (Th1)
and CD4+IL-17+ (Th17)] using flow cytometry. We ob-
served that 17-DMAG significantly inhibited intracellu-
lar expression of IFN-γ and IL-17A in anti-CD3
antibody-treated PBMCs, representing Th1 and Th17
cell fractions, respectively (Figure 2).
Figure 1 17-DMAG inhibits proliferation of T cells. A Proliferation
response of human PBMCs stimulated by plate-bound anti-CD3
antibody (1 μg/ml) in absence and presence of 17-DMAG. Cell cultures
were exposed to different concentrations of 17-DMAG and proliferation
was assayed by ELISA after BrdU incorporation on the 6th day of
treatment followed by 24 hours incubation. B LDH-based cytotoxicity
ELISA measurement in culture medium after 24-hour incubation of
PBMCs with different concentrations of 17-DMAG. LDH release from
cells lysed with 1% Triton X-100 was regarded as 100%. The results are
presented as mean values ± SEM of n= 4 healthy blood donors. *P<0.05.
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Using ELISA, we further measured the effects of 17-
DMAG on secretion of a broad array of PBMC-derived
cytokines (IL-2, IL-4, IL-5, IL-6, IL-10, IL-12, IL-13, IL-Figure 2 17-DMAG reduces frequencies of proinflammatory Th1 and
plate-bound anti-CD3 antibody in absence or presence of 17-DMAG (0.1 μM
last 5 hours of culture before permeabilization. Cells were washed, stained
flow cytometry. The numbers in upper right quadrants of the representativ
subpopulation. The results are presented as mean values ± SEM of n = 4 he17A, IFN-γ, TNF-α, G-CSF, and TGF-β1). The cytokines
were assayed in culture medium of PBMCs stimulated
with anti-CD3 antibody. The presence of 17-DMAG sig-
nificantly inhibited the secretion of the proinflammatory
cytokines IFN-γ (4.2-fold), TNF-α (2.8-fold), and IL-17A
(1.5-fold). We found no significant influence of 17-
DMAG on IL-2, G-CSF, and TGF-β1 secretion. The
remaining cytokines were below the detection limit of
the assay (Figure 3).
17-DMAG suppresses NFκB p65 activity
To test whether Hsp90 inhibition had an impact on
NFκB p65, its activity as well as protein expression was
measured in cell lysates of anti-CD3 antibody-stimulated
PBMCs by ELISA and immunoblotting, respectively.
Our results revealed that the addition of 17-DMAG
dose-dependently suppressed NFκB p65 activity without
affecting its protein level (Figure 4).
17-DMAG upregulates Hsp70 expression
To investigate whether 17-DMAG influenced the ex-
pression of Hsp70, a common marker of Hsp90 inhib-
ition, immunoblot analysis of lysates from anti-CD3
antibody-stimulated PBMCs was performed. Indeed, the
addition of 17-DMAG to these cell cultures resulted in
induction of Hsp70 protein expression (Figure 5).Th17 cell subpopulations. PBMCs were stimulated with 1 μg/ml of
) for 72 hours. GolgiStop™, PMA, and ionomycin were added in the
with anti-CD4, anti-IFN-γ, and anti-IL-17 antibodies, and analyzed by
e dot blots show the percentage of positive cells of each CD4+ T cell
althy blood donors. *P < 0.05.
Figure 3 17-DMAG arrests secretion of proinflammatory
cytokines. ELISA-based evaluation of the cytokines IL-2, IL-4, IL-5,
IL-6, IL-10, IL-12, IL-13, IL-17A, IFN-γ, TNF-α, G-CSF, and TGF-β1
secreted into the culture medium by PBMCs which were stimulated
with 1 μg/ml plate-bound anti-CD3 antibody and treated without or
with 17-DMAG (0.1 μM) for 72 hours. The results are presented as
mean values ± SEM of n = 3 healthy blood donors. The dotted line
represents the mean detection limit of the assay. *P < 0.05.
Figure 4 17-DMAG blunts NFκB p65 activity. Analysis of NFκB
p65 in PBMCs stimulated with 1 μg/ml plate-bound anti-CD3
antibody in absence and presence of different concentrations of
17-DMAG for 24 hours. NFκB p65 activity and protein expression
was analyzed in lysates of these cell cultures by ELISA and
immunoblotting, respectively. Protein concentration was expressed
relative to the β-actin level using densitometry measurements. The
results are presented as mean values ± SEM of n = 3 healthy blood
donors. *P < 0.05.
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To examine whether Hsp90 inhibition had an impact on
T cell-specific nonreceptor tyrosine kinase Lck, its phos-
phorylation status was measured in cell lysates of anti-
CD3 antibody-stimulated PBMCs by immunoblotting.
We demonstrated that the addition of 17-DMAG dose-
dependently suppressed Lck activation (Figure 6).
Discussion
Here, we provide evidence that 17-DMAG, upon non-
toxic concentrations, inhibited T cell proliferation and
reduced percentages of Th1 and Th17 cells, which was
associated with dampened Th1 (IFN-γ and TNF-α) and
Th17 (IL-17) cytokine secretion. These results are in
good agreement with previous studies reporting the
capacity of Hsp90 blockers to inhibit proliferation of T
lymphocytes ex vivo and to downregulate these proin-
flammatory T cell subtypes [4-11,13].
Since Th1 and Th17 cells are essential to the develop-
ment of various autoimmune diseases, treatment strat-
egies which aim at blocking of uncontrolled activation of
such effector cell populations are highly warranted [3]. In
fact, pharmacological blockade of Hsp90 has been
reported to be an effective treatment in rodent models of
T cell-mediated autoimmune diseases, such as auto-
immune encephalomyelitis [6], rheumatoid arthritis [7,8],
and systemic lupus erythematosus [9,10]. In addition, our
research group recently demonstrated that, by down-
regulating T cell responses, treatment with Hsp90 inhibi-
tors is also effective in mice with the experimentally
induced autoimmune bullous disease epidermolysis bul-
losa acquisita [11].
Although the main focus of our experiments was to
study the impact of 17-DMAG on Th1 and Th17 subpop-
ulations, we cannot rule out but also not support that 17-
DMAG additionally exhibited suppressive activity onother T cell populations such as Th2 and regulatory T
cells since Th2 cytokines released from anti-CD3
antibody-stimulated PBMCs were below the detection
limit of our assay and secreted IL-10 and TGF-β1, cyto-
kines associated with regulatory T cell function, were also
undetectable or not significantly inhibited in our study,
respectively. In this context, it is worth noting that there
is evidence in the recent literature that Hsp90 inhibition
can promote rather than inhibit regulatory T cells,
further supporting an antiinflammatory mechanism of
Figure 5 17-DMAG induces Hsp70 expression. Analysis of Hsp70
in PBMCs stimulated with 1 μg/ml plate-bound anti-CD3 antibody in
absence and presence of different concentrations of 17-DMAG for
24 hours. Hsp70 protein expression was analyzed in cell lysates
of these cell cultures by immunoblotting. Protein concentration
was expressed relative to the β-actin level using densitometry
measurements. The results are presented as mean values ± SEM of
n = 3 healthy blood donors. *P < 0.05.
Figure 6 17-DMAG disrupts Lck activation. Analysis of Lck in
PBMCs stimulated with 1 μg/ml plate-bound anti-CD3 antibody in
absence and presence of different concentrations of 17-DMAG for
24 hours. Lck phosphorylation at Tyr394 position was analyzed in
lysates of these cell cultures by immunoblotting. Protein
concentration was expressed relative to the β-actin level using
densitometry measurements. The results are presented as mean
values ± SEM of n = 3 healthy blood donors. *P < 0.05.
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[14,15].
Our current experiments further revealed that inhib-
ition of T cells by 17-DMAG was associated with deacti-
vation of NFκB and upregulation of Hsp70. While NFκB
is a client of Hsp90 and one of the major transcription
factors responsible for proliferation of T cells and their
proinflammatory IFN-γ and IL-17 expression [16,17],
Hsp70 is generally considered as a marker for effective
Hsp90 inhibition and also regarded as potent antiinflam-
matory chaperone capable of inhibiting NFκB signaling
pathways [18-20].
Corticosteroids, which are widely used to treat patients
with autoimmune diseases, mediate their immunosup-
pressive effects through cytosolic ligand-inducible gluco-
corticoid receptors. Inactive glucocorticoid receptors are
associated with (co)chaperones, including Hsp90, which
dissociate after their ligation, followed by nuclear trans-
location of these receptors and regulation of gene tran-
scription [21]. The glucocorticoid receptor has been
described as part of a T cell receptor-linked multiprotein
complex containing Hsp90 and the nonreceptor tyrosin
kinases Lck and Fyn, which is essential for T cell
receptor-dependent Lck/Fyn activation. It has beenpreviously shown that either treatment with dexametha-
sone or knocking down Hsp90 by Hsp90siRNA induces
dissociation of this protein complex, resulting in abro-
gated T cell receptor signaling as a consequence of im-
paired Lck/Fyn activation [22]. Similar to this and other
previous studies [4,13,22], we could show in the current
experiments that pharmacological blockade of Hsp90
was associated with inhibition of Lck activation in anti-
CD3 antibody-stimulated PBMCs, a mechanism that
could further account for the observed immunosuppres-
sive effects of this treatment on T cells.
Considering that inhibition of both NF-kB function
and proximal T cell receptor signaling by corticosteroids
can be mimicked using Hsp90 inhibitors and that a
novel generation of Hsp90 blockers with good tolerabil-
ity has been reported in the field of cancer treatment
[4,13,22-25], it remains to be clarified in the future
whether this class of drugs can potentially represent an
effective alternative for corticosteroid therapy with a bet-
ter side effect profile in patients with autoimmune
diseases.
Together, our results further support the potential use
of Hsp90 inhibitors in patients with autoimmune dis-
eases where inappropriate activation of proinflammatory
Th1 and Th17 subpopulations frequently occurs.
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